Showing results (261-270 of 293) with videos related to

Sort By:
Pageof 30
The Journal of Antimicrobial Chemotherapy|October 27, 2012
Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trialJyh-Ming Liou, Chieh-Chang Chen, Chi-Yang Chang, et al.
JHEP Reports : Innovation in Hepatology|January 26, 2024
Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infectionHarry L Janssen, Young-Suk Lim, Hyung Joon Kim, et al.
The American Journal of Gastroenterology|February 3, 2016
Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized TrialJyh-Ming Liou, Ming-Jong Bair, Chieh-Chang Chen, et al.
Gut|September 5, 2015
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of Helicobacter pylori in the community and hospital populations: a randomised trialJyh-Ming Liou, Chieh-Chang Chen, Chi-Yang Chang, et al.
The Journal of Antimicrobial Chemotherapy|May 31, 2018
14 day sequential therapy versus 10 day bismuth quadruple therapy containing high-dose esomeprazole in the first-line and second-line treatment of Helicobacter pylori: a multicentre, non-inferiority, randomized trialJyh-Ming Liou, Chieh-Chang Chen, Yu-Jen Fang, et al.
Alimentary Pharmacology & Therapeutics|October 26, 2023
Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational studyEiichi Ogawa, Dae Won Jun, Hidenori Toyoda, et al.
Therapeutic Advances in Gastroenterology|August 22, 2020
Comparison of the effect of clarithromycin triple therapy with or without N-acetylcysteine in the eradication of Helicobacter pylori: a randomized controlled trialChieh-Chang Chen, Jiing-Chyuan Luo, Yu-Jen Fang, et al.
The Lancet. Gastroenterology & Hepatology|December 22, 2022
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trialJyh-Ming Liou, Xiao-Tao Jiang, Chieh-Chang Chen, et al.
Lancet (London, England)|October 23, 2016
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trialJyh-Ming Liou, Yu-Jen Fang, Chieh-Chang Chen, et al.
Helicobacter|September 22, 2025
Overall and Stratified Accuracies of H. pylori Serology Testing: A Multicenter Study of 8497 Screening-Naïve AdultsMei-Jyh Chen, Yu-Jen Fang, Chien-Chuan Chen, et al.
Pageof 30